Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
        • Alopecia Areata
        • Atopic Dermatitis
        • Psoriasis
        • Diabetes
        • Hypoglycemia
      • Gastroenterology
      • Infectious Disease
      • Neuroscience
      • Oncology
      • Rheumatology
      • Tools for Communication
      • All Therapeutic Areas
      • Dermatology
        • Diabetes
        • Hypoglycemia
      • Neuroscience
      • Oncology
      • Osteoporosis
      • Rheumatology
      • Well-Being
  • Chat Contact Us

DIAGNOSIS

PATIENT BURDEN

JAK-STAT PATHWAY

IMMUNE PRIVILEGE

Patient Burden

A person with alopecia totalis, no hair on the scalp, eyelashes, eyebrows or face

There are currently no FDA-approved treatments for alopecia areata1

Current treatment guideline recommendations include topical immunotherapy, topical corticosteroids, intralesional corticosteroids, oral corticosteroids, phototherapy, and systemic therapies2,3

There are a host of complex needs that are unmet for patients with alopecia areata1,4-17:

  • Psychiatric co-morbidities (such as anxiety, depression, and suicide) and impacts on relationships (bullying, family, and places of employment)
  • There are multiple sociocultural implications (religious significance, cultural stigma, social symbols of youth/vigor, representation of sexual maturity and reproduction) and physical co-morbidities (temperature control, environmental protection, sense of touch, and autoimmune and inflammatory disorders) that impact quality of life
  • There is also a potential for significant financial considerations in managing alopecia areata.18

Related resources

Chapter 1: Unmet needs in Alopecia Areata

This video animation summarizes the unmet needs of patients with alopecia areata.

References

  1. U.S. Food & Drug Administration. The voice of the patient: a series of reports from FDA’s patient-focused drug development initiative: alopecia areata. Accessed March 5, 2019.
  2. Strazzula LC, Chun Wang EH, Avila L, et al. An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018b;78:15-24. doi:10.1016/j.jalopecia areatad.2017.04.1142
  3. Meah N, Wall D, York K, et al. The alopecia areata consensus of experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123-130. doi:10.1016/j.jaad.2020.03.004
  4. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. doi:10.1038/nrdp.2017.11
  5. Strazzula LC, Chun Wang EH, Avila L, et al. Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018a;78:1-12. doi:10.1016/j.jalopecia areatad.2017.04.1141
  6. Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families. J Am Acad Dermatol. 2018;S0190-9622. doi:10.1016/j.jalopecia areatad.2018.01.048
  7. Fricke ACV, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403. doi:10.2147/CCID.S53985
  8. Lee YB, Lee WS. Alopecia areata and itch: a retrospective analysis of 312 cases. J Eur Acad Dermatol Venereol. 2019;33:e317-e319. doi:10.1111/jdv.15591
  9. Vélez-Muñiz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, et al. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord. 2019;5(5):293-298. doi:10.1159/000497166
  10. Abedini R, Hallaji Z, Lajevardi V, et al. Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol. 2017;4(2):91-94. doi:10.1016/j.ijwd.2017.07.001
  11. Layegh P, Arshadi HR, Shahriari S, et al. A comparative study on the prevalence of depression and suicidal ideation in dermatology patients suffering from psoriasis, acne, alopecia areata and vitiligo. Iran J Dermatol. 2010;13:106-111.
  12. Jagtiani A, Nishal P, Jangid P, et al. Depression and suicidal ideation in patients with acne, psoriasis, and alopecia areata. J Mental Health Hum Behav. 2017;22(1):50-54. doi:10.4103/0971-8990.210700
  13. Buffoli B, Rinaldi F, Labanca M, et al. The human hair: from anatomy to physiology. Int J Dermatol. 2014;53(3):331-341. doi:10.1111/ijd.12362
  14. Santos Z, Avci P, Hamblin MR. Drug discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov. 2015;10(3):269-292. doi:10.1517/17460441.2015.1009892
  15. Azzawi S, Penzi LR, Senna MM. Immune privilege collapse and alopecia development: is stress a factor? Skin Appendage Disord. 2018;4(4):236-244. doi:10.1159/000485080
  16. Karthikeyan K. Tonsuring: Myths and facts. Int J Trichology. 2009;1(1):33-34. doi:10.4103/0974-7753.51927
  17. BBC. The Five Ks. Published 2009. Accessed August 25, 2020. https://www.bbc.co.uk/religion/religions/sikhism/customs/fiveks.shtml
  18. Li SJ, Mostaghimi A, Tkachenko E, Huang KP. Association of out-of-pocket health care costs and financial burden for patients with alopecia areata. JAMA Dermatol. 2019;155(4):493-494. doi:10.1001/jamadermatol.2018.5218

VV-MED-125306

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.0.3 08/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Facebook Twitter
Lilly